GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.

GLORIA is funded by the EU Horizon 2020 Program. >> 

NEWS

GLORIA's article published by Oxford University Press

Our article entitled "Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study" has just been published by Oxford University Press. Please click on the following link to view the abstract: https://academic.oup.com/rheumatology/article-abstract/60/7/333
Read more